Bausch & Lomb Reports Second Quarter 2026 Financial Results

Second Quarter 2026 Earnings Announcement

Bausch & Lomb Corporation issued a formal announcement on July 29, 2026, regarding its operational and financial performance for the second quarter of fiscal year 2026. The disclosure was made through a press release that detailed results of operations and other material financial information pertaining to the quarter ended June 30, 2026. This announcement represents the company's regular reporting of quarterly financial performance to shareholders and the investment community. The filing itself serves as a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the company's compliance with ongoing disclosure obligations.

The company, headquartered in Vaughan, Ontario, Canada, operates as a significant player in the eye health and ophthalmic care sector. Bausch & Lomb's dual listing on the New York Stock Exchange under ticker BLCO and the Toronto Stock Exchange provides investors on both sides of the North American market direct access to its securities. The July 29 announcement follows the company's standard quarterly reporting cycle and provides transparency regarding operational results during the second quarter period.

Corporate Structure and Exchange Listings

Bausch & Lomb maintains its incorporation in Canada and operates with a principal executive office location in Vaughan, Ontario. The company's dual listing on the NYSE and Toronto Stock Exchange reflects its significant presence in North American capital markets. As of the filing date, the company holds Commission File Number 001-41380 with the Securities and Exchange Commission, and its IRS Employer Identification Number is 98-1613662. This regulatory standing ensures the company meets the disclosure and compliance requirements imposed on publicly traded entities in the United States.

The company's securities structure consists of Common Shares with no par value, traded under the symbol BLCO on both exchanges. This dual-listing arrangement provides liquidity and accessibility for investors across Canada and the United States. The company is not classified as an emerging growth company under Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934, indicating it operates under the full regulatory framework applicable to mature public companies.

Financial Information Disclosure Details

The announcement released on July 29, 2026, contained results of operations and certain other financial information as of and for the quarter ended June 30, 2026. The company did not disclose specific revenue figures, earnings metrics, or other quantitative financial results in the current report filed with the SEC. Investors seeking detailed financial data would need to review the attached press release, which is incorporated by reference in the filing. This press release represents the primary source document through which the company presented its quarterly financial performance to the public market.

According to SEC regulations governing disclosure of financial condition information, the content presented in Item 2.02 of this report, including the press release exhibit, is furnished for informational purposes and is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. This distinction means the information, while material and disclosed to the market, carries different liability implications than information formally filed under section 18. Nevertheless, the disclosure remains subject to antifraud provisions and represents the company's official communication regarding its quarterly operational and financial performance.

Regulatory Filing Classification

Bausch & Lomb submitted a Current Report on Form 8-K with the Securities and Exchange Commission on July 29, 2026, to announce its second quarter results. The filing was signed by Sam Eldessouky, Executive Vice President and Chief Financial Officer, on behalf of the company. This current report filing satisfies the company's obligation to disclose material information regarding results of operations and financial condition within the timeframe required by securities regulations. The submission demonstrates the company's continued compliance with mandatory periodic reporting requirements imposed on publicly traded entities.

The Current Report filing includes exhibits necessary to provide complete disclosure to investors. Exhibit 99.1 contains the press release announcing the financial results for the second quarter of 2026. Additionally, Exhibit 104 includes the Cover Page Interactive Data File formatted as Inline XBRL, which provides machine-readable financial and corporate information in a standardized format. This XBRL data format enhances accessibility for financial professionals, regulators, and technology platforms that process corporate disclosure documents.

Press Release as Primary Disclosure Vehicle

The press release attached to the filing serves as the principal mechanism through which Bausch & Lomb conveyed its second quarter 2026 financial results to investors and the broader market. The company dated this press release July 29, 2026, coinciding with the date of the regulatory filing. By incorporating the press release as an exhibit to the current report, the company ensured simultaneous disclosure across both SEC channels and traditional investor relations communication methods. This approach provides transparency and equal access to financial information for all market participants.

The specific operational metrics, revenue figures, earnings per share data, and other quantitative financial information referenced in the press release would contain the detailed performance analysis investors require for informed decision-making. The company did not disclose these specific figures within the body of the regulatory filing itself, instead relying on the attached exhibit to convey the detailed financial narrative. Investors and analysts reviewing the announcement would need to examine the press release document to access the complete financial picture for the second quarter ended June 30, 2026.

Market Context and Investor Monitoring

Bausch & Lomb operates in the ophthalmic care and eye health sector, a market characterized by steady demand for both pharmaceutical and device-based solutions. The second quarter results announcement provides visibility into the company's operational performance during the first half of 2026. The timing of the July 29 disclosure aligns with standard corporate reporting practices and allows investors to assess performance metrics and trends relevant to the company's competitive position within its industry. The filing does not indicate whether the company's results met, exceeded, or fell short of market expectations, as specific guidance and performance metrics are contained in the accompanying press release.

The immediate share price impact was not clear from available public information contained in the regulatory filing itself. Market reaction to the announcement would typically reflect investor interpretation of the financial results disclosed in the press release relative to prior expectations and guidance. Professional analysts and institutional investors monitor such quarterly announcements as key data points in evaluating the company's fundamental performance, operational efficiency, and trajectory within its sector. The dual listing provides these investors with multiple trading venues through which to transact on any investment decisions resulting from the disclosed financial information.

Filing Status and Investor Implications

The Current Report filing confirms that Bausch & Lomb maintains compliance with its periodic reporting obligations under United States securities laws. The company does not qualify as an emerging growth company, meaning it operates under the standard disclosure regime applicable to mature public companies. This regulatory status ensures investors receive the comprehensive financial and operational reporting required for informed investment decisions. The filing was executed without checking any of the optional boxes related to securities act or exchange act pre-commencement communications, indicating the announcement represented routine quarterly reporting rather than disclosure related to special transactions or corporate actions.

Investors reviewing this announcement should note that the financial condition information provided through Item 2.02 and the accompanying press release is furnished for informational purposes, with the specific liability protections and constraints that designation entails under securities law. The information does not constitute a guarantee of future performance and should be evaluated in conjunction with historical financial data, management guidance, and broader industry context. Those interested in the complete financial analysis would need to review the press release exhibit directly for detailed metrics, management commentary, and any forward-looking statements regarding the company's performance trajectory.

Operational Timing and Reporting Schedule

The announcement of second quarter results on July 29, 2026, represents the company's standard quarterly reporting cadence. The June 30, 2026 quarter-end date aligns with the company's established fiscal calendar and enables consistent comparability of results across periods. This timing allows investors and analysts to assess sequential quarter-over-quarter performance and year-over-year trends within the ophthalmic care industry. The prompt disclosure of results following the quarter-end date demonstrates management's commitment to timely communication with shareholders and market participants.

Bausch & Lomb's reporting schedule and disclosure practices position the company within established norms for publicly traded corporations operating in the healthcare and medical device sectors. The company did not disclose information regarding future guidance, management plans, or strategic initiatives beyond the results disclosed for the reported quarter. Investors monitoring the company should continue to observe subsequent announcements and periodic filings for updates regarding operational direction, capital allocation decisions, or other material corporate developments that may emerge in coming periods.